Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1

Interventions

Trastuzumab 18Radiosurgery 15Capecitabine 13Lapatinib 11Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 7Temozolomide 6tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Vinorelbine 4Specimen Handling 4Paclitaxel 4Methotrexate 4Cisplatin 4sacituzumab govitecan 3pyrotinib 3abemaciclib 3Radiation 3Fluorodeoxyglucose F18 3pertuzumab 2palbociclib 2neratinib 2durvalumab 2cediranib 2cabazitaxel 2Sodium Chloride 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × etirinotecan pegol × Breast × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡